This document summarizes information about the COVID-19 vaccines Covaxin and Covishield. Covaxin was developed by Bharat Biotech in India using an inactivated virus platform, while Covishield was developed by Oxford-AstraZeneca and is manufactured by Serum Institute of India using a viral vector platform. Both vaccines require two doses, with the second dose of Covaxin administered 4-6 weeks after the first and Covishield 12-16 weeks after. Effectiveness is reported as 81% for Covaxin and 90% for Covishield based on clinical trials. Common minor side effects include fever, fatigue, headache and pain at the injection site.

1. PRESENTED BY:
AMAN SINGH CHAUHAN
COURSE : B.SC (ZBC)
SEMESTER : 4
COLLEGE : INVERTIS UNIVERSITY ,
BAREILLY
COVID 19VACCINE

2. .
NOVEL CORONAVIRUS
COVID 19 CORONA VIRUS DISEASE 2019
OFFICIAL NAME severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2)
NAME OFVIRUS GIVEN BY :
viruses are named by the International
Committee onTaxonomy ofViruses (ICTV).

3. .What is vaccination ?
 Vaccination is a simple, safe, and effective way of
protecting people against harmful diseases, before they
come into contact with them. It uses your body’s
natural defenses to build resistance to specific
infections and makes your immune system stronger.
 Vaccines train your immune system to create
antibodies, just as it does when it’s exposed to a
disease. However, because vaccines contain only killed
or weakened forms of germs like viruses or bacteria,
they do not cause the disease or put you at risk of its
complications.
 Most vaccines are given by an injection, but some are
given orally (by mouth) or sprayed into the nose.

4. .
Covaxin vs Covishield
DEVELOPER :
 Covaxin has been developed by Hyderabad-based
Bharat Biotech International Ltd in association with
the Indian Council of Medical Research (ICMR) and
the National Institute ofVirology (NIV).
 Covishield has been developed by the Oxford-
AstraZeneca and is being manufactured by the
Serum Institute of India (SII).

5. .
Type ofVaccine
1 Covaxin is an inactivated viral vaccine.This vaccine is
developed withWhole-Virion InactivatedVero Cell-derived
technology.They contain inactivated viruses, which can not
infect a person but still can teach the immune system to
prepare a defence mechanism against the active virus.
 These conventional vaccines have been in use for decades
now.There are vaccines for some other diseases as well
which are made using the same technology.These diseases
are –
 Seasonal influenza
 Rabies
 Polio
 Pertussis, and
 Japanese encephalitis

6. .
2 . COVISHIELD
Covishield has been prepared using the viral vector
platform which is a totally different technology.
 A chimpanzee adenovirus – ChAdOx1 – has been
modified to enable it to carry the COVID-19 spike
protein into the cells of humans. Well, this cold virus
is basically incapable of infecting the receiver but
can very well teach the immune system to prepare a
mechanism against such viruses.
 The exact technology was used to prepare vaccines
for viruses like Ebola.

7. Doses
 There is no difference between the two vaccines in
terms of dosage. Both of them are administered as
0.5ml in the upper arm region.
 But, the dosing schedule for both vaccines however
varies.The second dose of Covaxin is scheduled
after 4-6 weeks after the first dose, while for
Covishield vaccines it is 84 days or 12-16 weeks
after the first dose.

8. Efficacy
 Both the vaccines have shown more than
satisfactory results ever since the inoculation
started in India.
 The effectiveness of the Covishield vaccine is nearly
90% as per the global reports and Covaxin’s 81%
according to interim 3rd phase trial results.

9. ,
Side effects
 After getting vaccinated, people may experience side
effects such as :
 fever
 fatigue
 headache
 muscle pain
 chills
 diarrhoea
 pain at the injection site.
These side effects do not persist for long and generally
go within a day or two.

10. .

11. .
How vaccine acts on covid 19 virus :
corona virus Antibodies
Antibodies attached to spike protein

12. THANKYOU